Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma

PURPOSE: To determine the antitumor efficacy and tolerability of combination temozolomide (TMZ) and veliparib (ABT-888) in patients with advanced, sorafenib-refractory hepatocellular carcinoma (HCC). METHODS: This single-arm phase II trial enrolled patients with pathologically confirmed, sorafenib-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabrielson, Andrew, Tesfaye, Anteneh A., Marshall, John L., Pishvaian, Michael J., Smaglo, Brandon, Jha, Reena, Dorsch-Vogel, Karen, Wang, Hongkun, He, Aiwu Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612326/
https://www.ncbi.nlm.nih.gov/pubmed/26449224
http://dx.doi.org/10.1007/s00280-015-2852-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612326/
https://www.ncbi.nlm.nih.gov/pubmed/26449224
http://dx.doi.org/10.1007/s00280-015-2852-2

Ejemplares similares